Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR7280 in Hormone Sensitive Prostate Cancer
NCT04995042Phase 1Completed
- Sponsor
- Hengrui
- Start
- Sep 2021
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SHR7280 in prostate cancer (PCa), sponsored by Hengrui. Primary endpoints: Adverse Events, Dose Limiting Toxicity at 28 days and 2 more. Started Sep 2021; status: completed.
02
Drugs
SHR7280
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04995042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04995042.